StockMarketWire.com - Sensyne Health said it had entered into a new strategic partnership with Evotec, the University of Oxford and Oxford Sciences Innovation.

The initiative, dubbed LAB10x, would attempt to accelerate the translation of research in the fields of clinical artificial intelligence and digital health at Oxford into breakthrough digital therapeutics.

The partners would also aim to develop clinical AI algorithms and to accelerate data-driven drug discovery and development.

Projects would be sourced exclusively from University of Oxford researchers and be aided by an expert in residence seconded by Sensyne Health.

The technologies developed by LAB10x would be applied to generate and analyse anonymised patient datasets to improve patient outcomes and accelerate medical research and pharmaceutical R&D.

LAB10x would be supported by a fund of £5m for an initial period of three years.


At 8:29am: [LON:SENS] Sensyne Health Plc Ord 10p share price was +1.5p at 124p



Story provided by StockMarketWire.com